Cyltezo

Digital Pharmacist

The RxWiki Digital Pharmacist stamp of approval lets you know that this content has been created and reviewed by a licensed pharmacist.

Cyltezo helps treat the symptoms of certain types of arthritis, Crohn's disease, and other immune disorders. How often you take Cyltezo depends on what you are taking it for.

Cyltezo Overview

Reviewed: November 8, 2017
Updated: 

Cyltezo is a prescription medication used to relieve the symptoms of some autoimmune disorders. It is used to treat certain types of arthritis, Crohn's disease, ulcerative colitis, and plaque psoriasis. 

Cyltezo belongs to a group of drugs called tumor necrosis factor (TNF) inhibitors. These work by decreasing TNF action in the body which decreases inflammation in the body. Cyltezo is a biosimilar (closely related) product to Humira (adalimumab).

This medication comes in an injectable form in prefilled syringes. Cyltezo is injected just under the skin usually once every other week.

Common side effects of Cyltezo include infection, reaction at the site of injection, and headache.

How was your experience with ?

First, a little about yourself

Tell us about yourself in a few words?

What tips would you provide a friend before taking ?

What are you taking for?

Choose one
  • Other

How long have you been taking it?

Choose one
  • Less than a week
  • A couple weeks
  • A month or so
  • A few months
  • A year or so
  • Two years or more

How well did work for you?

Did you experience many side effects while taking this drug?

How likely would you be to recommend to a friend?

Cyltezo Drug Class

Back to Top

Cyltezo is part of the drug class:

Cyltezo FDA Warning

Back to Top

SERIOUS INFECTIONS 

  • Increased risk of serious infections leading to hospitalization or death, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens.  
  • Discontinue Cyltezo if a patient develops a serious infection or sepsis during treatment.  
  • Perform test for latent TB; if positive, start treatment for TB prior to starting Cyltezo.
  • Monitor all patients for active TB during treatment, even if initial latent TB test is negative.

MALIGNANCY

  • Lymphoma and other malignancies, some fatal, have been reported in children and adolescent patients treated with TNF blockers including adalimumab products.  
  • Post-marketing cases of hepatosplenic T-cell lymphoma (HSTCL), a rare type of T-cell lymphoma, have occurred in adolescent and young adults with inflammatory bowel disease treated with TNF blockers including adalimumab products.